Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH)

Published:2019-04-10 Issue:6 Volume:102 Page:465-471
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

García-Cadenas Irene¹^ORCID,Yáñez Lucrecia²,Jarque Isidro³,Martino Rodrigo¹,Pérez-Simón Jose Antonio⁴,Valcárcel David⁵,Sanz Jaime³,Bermúdez Arantxa²,Muñoz Cristina⁶,Calderón-Cabrera Cristina⁴,García Estefania⁷,Alonso Laura⁵,Suárez-Lledó Maria⁸,González Vicent Marta⁹,Heras Inmaculada¹⁰,Viguria Mª Cruz¹¹,Batlle Montserrat¹²,Vázquez Lourdes¹³,López Javier¹⁴,Solano Carlos¹⁵,

Affiliation:

1. Department of Hematology of the: Hospital de la Santa Creu I Sant Pau, Biomedical Research Institute (IIB Sant-Pau); Autonomous University of Barcelona; Barcelona Spain

2. HU. Marqués de Valdecilla; Santander Spain

3. Hospital La Fe; Valencia Spain

4. HU. Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC/CIBERONC); Universidad de Sevilla; Sevilla Spain

5. Hospital Vall d’Hebrón; Barcelona Spain

6. Hospital Gregorio Marañón; Madrid Spain

7. Hospital Reina Sofía; Cordoba Spain

8. Hospital Clínic Barcelona; Barcelona Spain

9. Hospital Niño Jesús; Barcelona Spain

10. Hospital Morales Meseguer; Murcia Spain

11. Complejo Hospitalario de Navarra; Pamplona Spain

12. H. Germans Trias i Pujol; Barcelona Spain

13. H. Clínico Universitario de Salamanca; Salamanca Spain

14. H. Ramón y Cajal; Madrid Spain

15. Hospital Clínico de Valencia; Valencia Spain

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.13226/fullpdf

Reference43 articles.

1. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study;Curtis;Blood,1999

2. Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab;Patriarca;Transpl Infect Dis,2013

3. Identifying the patient at risk for post-transplant lymphoproliferative disorder;Cockfield;Transpl Infect Dis,2001

4. Response to rituximab-based therapy and risk factor analysis in Epstein Barr virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation;Styczynski;Clin Infect Dis,2013

5. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation;Coppoletta;Biol Blood Marrow Transplant,2011

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative analysis of tabelecleucel and current treatment in patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease following hematopoietic cell transplant or solid organ transplant;Journal of Medical Economics;2024-06-03

2. Immune deficiency/dysregulation -associated lymphoproliferative disorders. Revised classification and management;Blood Reviews;2024-03

3. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial;The Lancet Oncology;2024-03

4. Rituximab for posttransplant lymphoproliferative disorder – therapeutic, preemptive, or prophylactic?;Bone Marrow Transplantation;2023-11-25

5. Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy;Bone Marrow Transplantation;2023-10-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3